Patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) do not have a higher risk of major adverse cardiovascular events (MACE) with ertugliflozin, according to results of the phase III VERTIS CV* trial.
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Dapagliflozin reduced the incidence of new-onset type 2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF), according to a prespecified exploratory analysis of the DAPA-HF* trial.
The use of insulin detemir among women with pre-existing diabetes was not associated with an increased risk of negative pregnancy outcomes, such as major congenital malformations and perinatal or neonatal deaths, compared with other basal insulins, according to the EVOLVE* study.
The next-generation automated insulin delivery (AID) system significantly improved daytime glycaemic control without increasing hypoglycaemia over the current 670G hybrid closed-loop system on the market in young patients with type 1 diabetes (T1D), according to the FLAIR* trial presented during the ADA 2020 Annual Meeting.
Women who follow a healthy plant-based diet before pregnancy have a lower risk of developing gestational diabetes mellitus (GDM), suggests a large, prospective cohort study presented at the ADA 2020 Annual Meeting.
The novel dual-acting glucokinase activator (GKA) dorzagliatin provides good glycaemic control and has a favourable safety profile in Chinese patients with type 2 diabetes (T2D), the phase III SEED* study has shown.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.